However, with the development of novel therapeutics for AML, it would be reasonable to employ diagnostic and therapeutic strategies learned from the APL and IDH-mutated AML experiences followed by an iterative approach that incorporates emerging clinical findings [15,21]. This evidence concerns the gene IDH2 and acute promyelocytic leukemia.